Published Online:14 Nov 2013https://doi.org/10.4155/tde.13.102
Abstract
All research investment has the goal of improving quality of life and health status. In recent years, the emerging technologies in nanomedicine research provide us a new frontier in the fight against human disease. By taking advantage of the unique physicochemical properties of nanoparticles (NPs), nanomedicine where drugs are blended into nanomaterials readily offers a wide range of applications in the tracing, diagnosis and treatment of disease. Although the application of therapeutic NPs is predominantly for cancer treatment, growing evidence has demonstrated the feasibility and potency of utilizing NPs for cardiovascular disease therapy. However, more consideration is required in this aspect due to limitations such as unfavorable particle retention in the contractile heart and the lack of cardiomyocyte markers for targeting.
References
- 1 The WHO. Fact sheet No. 317 March 2013. The WHO, Geneva, Switzerland (2013).Google Scholar
- 2 Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics–2013 update: a report from the American heart association. Circulation127(1),e6–e245 (2013).Crossref, Medline, Google Scholar
- 3 Gupta A. Nanomedicine approaches in vascular disease: a review. Nanomedicine7(6),763–779 (2011).Crossref, Medline, Google Scholar
- 4 Garbern JC, Lee RT. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell12(6),689–698 (2013).Crossref, Medline, CAS, Google Scholar
- 5 Levchenko TS, Hartner WC, Torchilin VP. Liposomes for cardiovascular targeting. Ther. Deliv.3(4),501–514 (2012).Link, CAS, Google Scholar
- 6 Psarros C, Lee R, Margaritis M, Antoniades C. Nanomedicine for the prevention, treatment and imaging of atherosclerosis. Nanomedicine8(Suppl. 1),S59–S68 (2012).Crossref, Medline, CAS, Google Scholar
- 7 Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat. Rev. Drug Discov.10(11),835–852 (2011).Crossref, Medline, CAS, Google Scholar
- 8 Chang MY, Yang YJ, Chang CH et al. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J. Control. Release170(2),287–294 (2013).Crossref, Medline, CAS, Google Scholar
- 9 Bonvini RF, Hendiri T, Camenzind E. Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target? Eur. Heart J. Suppl.7(Suppl. I),I27–I36 (2005).Crossref, CAS, Google Scholar
- 10 Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int. J. Cardiol.130(2),147–158 (2008).Crossref, Medline, Google Scholar
- 11 Basarkar A, Singh J. Poly (lactide-co-glycolide)-polymethacrylate nanoparticles for intramuscular delivery of plasmid encoding interleukin-10 to prevent autoimmune diabetes in mice. Pharm. Res.26(1),72–81 (2009).Crossref, Medline, CAS, Google Scholar
- 12 Bowey K, Tanguay F, Tabrizian M. Liposome technology for cardiovascular disease treatment and diagnosis. Expert Opin. Drug Deliv.9(2),249–265 (2012).Crossref, Medline, CAS, Google Scholar
- 13 Lee D, Bae S, Hong D et al. H2O2-responsive molecularly engineered polymer nanoparticles as ischemia/reperfusion-targeted nanotherapeutic agents. Sci. Rep.3,2233 (2013).Crossref, Medline, Google Scholar
- 14 Liu J, Gu C, Cabigas EB et al. Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction. Biomaterials34(14),3729–3736 (2013).Crossref, Medline, CAS, Google Scholar
- 15 Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc. Chem. Res.44(10),842–852 (2011).Crossref, Medline, CAS, Google Scholar
- 16 Caruthers SD, Cyrus T, Winter PM, Wickline SA, Lanza GM. Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.1(3),311–323 (2009).Crossref, Medline, CAS, Google Scholar
- 17 Chan JM, Zhang L, Tong R et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc. Natl Acad. Sci. USA107(5),2213–2218 (2010).Crossref, Medline, CAS, Google Scholar
- 18 Dvir T, Bauer M, Schroeder A et al. Nanoparticles targeting the infarcted heart. Nano Lett.11(10),4411–4414 (2011).Crossref, Medline, CAS, Google Scholar
- 19 Jukanti R, Devaraj G, Devaraj R, Apte S. Drug targeting to inflammation: studies on antioxidant surface loaded diclofenac liposomes. Int. J. Pharm.414(1–2),179–185 (2011).Crossref, Medline, CAS, Google Scholar
- 20 Liu H, Slamovich EB, Webster TJ. Less harmful acidic degradation of poly(lacticco-glycolic acid) bone tissue engineering scaffolds through titania nanoparticle addition. Int. J. Nanomed.1(4),541–545 (2006).Crossref, Medline, CAS, Google Scholar
